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Gi et al. recently published an in vivo genotoxicity study of 1,4-dioxane, examining, amongst other 
endpoints, treatment-induced transgene mutations in the livers of gpt delta rats (Gi et al. 2018). The 
authors employed the BMDS and PROAST software packages to analyze the dose-response data and 
determine a point of departure (PoD) metric known as the BMD or Benchmark Dose. With respect to 
BMDS, the authors used one standard deviation of the concurrent control group as the benchmark 
response (BMR), and determined the lower confidence limit of the BMD1SD (i.e., the BMDL1SD). With 
respect to PROAST, they used 10% increase over the mean concurrent control group as the BMR, also 
known as the Critical Effect Size (CES), and determined the lower confidence limit of the BMD10 (i.e., 
the BMDL10). The authors also examined the no observed effect level (NOEL), the highest tested dose 
that failed to elicit a significant increase in response relative to the concurrent control.  
The authors’ interpretation of the aforementioned PoD metrics involved quantitative comparisons of 
the NOEL, the BMDL10, and the BMDL1SD. Although the analyses and interpretation of the results are 
interesting, there are several weaknesses in the presentation and interpretation of the BMD values. 
The authors correctly specify the advantages of the BMD approach relative to the NOEL approach, 
highlighting the inability to calculate a confidence limit on a NOEL from a single study, yet they did 
not examine or discuss the confidence intervals associated with the BMD values (i.e., the upper and 
lower confidence limits). This is critically important since it provides a means for determining the 
precision of the BMD; moreover, it’s utility for risk assessment and regulatory decision-making. More 
specifically, the ratio of the BMDU to the BMDL provides information about the uncertainty of the 
BMD, which in turn reflects the quality of the underlying dose-response data (Wills et al. 2017). 
Indeed, it has been suggested that the magnitude of uncertainty of the BMD estimate, as indicated 
by the BMDL to BMDU ratio, should be used as a tool for evaluating the statistical quality of the 
underlying data (Benford et al. 2010), and the utility of a BMDL as a reference PoD for regulatory 
decision-making (Barlow et al. 2006; Benford et al. 2010).  
In order to scrutinise the precision of the BMD estimates presented by the authors, we reanalysed 
the data presented in Table 2, and examined the BMDL to BMDU ratios as indicators of BMD 
precision, and the statistical quality of the underlying experimental data.  The results obtained 
revealed BMDL10 to BMDU10 ratios of 350 and 3736 for the exponential and hill models, respectively. 
These values indicate, in our opinion, that the dose-response data presented by the authors are not 
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suitable for determination of a BMDL10 that can be used as a reference PoD for regulatory decision-
making. Additionally, the authors’ comparison of the NOEL and the BMDL10 is problematic since it 
gives the reader the false impression that the BMD approach may yield a far more conservative PoD. 
Indeed, the NOEL is actually within the BMD10 confidence interval (i.e., BMDL10 to BMDU10).  
Careful consideration of the aforementioned uncertainty in the BMD10 (i.e., the BMDL10 to BMDU10 
ratio) reveals that the low BMDL10 is a consequence of (1) the large amount of variability in the dose-
specific responses, and (2) the low CES selected by the authors. Accordingly, the BMDL10 should not 
be interpreted as conservative, but rather reflective of BMD imprecision. Furthermore, with respect 
to the BMD1SD approach, it is not at all surprising, given the large variability in the control responses 
for experiment 1, that the value is much higher than the BMD10 (i.e., 576 ppm versus 0.98 ppm). 
More specifically, the ratio of the standard deviation to the mean is 0.6, corresponding to a BMR, 
when expressed as a percentage relative to control, of 60%. Consequently, the BMDL1SD, which is 
quantitatively analogous to a BMDL60, is far greater than the BMDL10. Thus, as already indicated 
above, it is critically important to (1) examine complete BMD confidence intervals (i.e., BMDL to 
BMDU), and (2) select a CES that is appropriate for the endpoint under consideration. With respect 
to the latter, recent analyses indicate that a CES of 10% is too low for the genetic toxicity endpoint 
examined; moreover, that a CES in the range of 40-50% is more appropriate for the interpretation of 
transgenic rodent mutagenicity dose-response data (Zeller et al. 2017). Reanalysis of the Gi et al. 
data with a CES of 50% yields BMDL and BMDU values of 23 and 2030 ppm for the exponential model, 
and 171 and 2490 ppm for the hill model; resultant BMDL to BMDU ratios for the exponential and hill 
models are 88.3 and 14.6, respectively. Accordingly, the use of an appropriate, endpoint-specific CES 
yields more precise BMD values, and a BMDL values that can be deemed more suitable for regulatory 
decision-making; moreover, a regulatory decision based on a PoD that is not restricted to one of the 
studied doses. 
In conclusion, although it is clear that Gi and colleagues have presented interesting, important 
information regarding the genetic toxicity of 1,4-dioxane, their interpretation of the BMD analysis is 
problematic in several respects. They only note the lower confidence limits of the BMD values, which, 
as noted, can give the false impression that the BMD approach yields conservative values. Relatedly, 
interpretation of the NOEL1 via comparison with the lower confidence limit of the BMD10, gives the 
contrasting false impression that the NOEL is less conservative. When using the BMD approach for 
regulatory interpretation of genetic toxicity dose-response data, we unequivocally recommend 
uniform examination of the complete BMD confidence interval, and, in particular, the BMDL to 
BMDU ratio. This ratio is critically important for appropriate interpretation of BMD reliability, and, by 
extension, for determining the regulatory utility of the underlying dose-response data. Lastly, going 
forward, it is clear that future work should scrutinise all available dose-response data in an effort to 
determine CES values that are appropriate for genetic toxicity endpoints. 
                                                          
1It should be noted that reanalysis of the data presented in Table 2 yielded a NOEL of 1000ppm. For details 
about the approach employed for NOEL determination see Johnson et al., 2014 (Johnson et al. 2014). 
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